专利检索 ap:("Bausch Health Ireland Limited") AND inv:"Lorin K. Johnson" 第 1 页

1.

发明申请
USE OF METHYLNALTREXONE AND RIFAXIMIN FOR TREATMENT OF INCREASED GUT PERMEABILITY OR ASSOCIATED DISORDERS 有权

公开(公告)号：US20220175764A1

公开(公告)日：2022-06-09

申请号：US17529818

申请日：2021-11-18

申请人： Bausch Health Ireland Limited

发明人： Lorin K. Johnson , XiaoJun Nicole Deng , William J. Jo Siu , Robert J. Israel , Zeev Heimanson

IPC分类号： A61K31/485 , A61K31/437 , A61P1/16 , A61P1/00

摘要： The present disclosure is directed to the use of methylnaltrexone, or a salt thereof, and rifaximin for the treatment of increased gut permeability, or an associated disorder, e.g., NASH or NAFLD.